Favipiravir/levofloxacin/paracetamolSevere thrombocytopenia and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1886卷 / 1期

关键词：

D O I：

10.1007/s40278-021-07455-1

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：190 / 190

相关论文

共 50 条

[1] Favipiravir/voriconazoleHyperuricaemia, transaminitis and off-label use: case report
Reactions Weekly, 2021, 1838 (1) : 223 - 223
[2] Favipiravir/hydroxychloroquineUrticaria, angioedema and off-label use: case report
Reactions Weekly, 2023, 1962 (1) : 185 - 185
[3] Azithromycin/favipiravir/hydroxychloroquineLack of efficacy and off-label use: case report
Reactions Weekly, 2021, 1865 (1) : 104 - 104
[4] Ceftriaxone/favipiravir/vancomycinLack of efficacy and off-label use: case report
Reactions Weekly, 2022, 1912 (1) : 141 - 141
[5] CapecitabineHyperbilirubinaemia and thrombocytopenia following off-label use: case report
Reactions Weekly, 2021, 1861 (1) : 85 - 85
[6] Ceftriaxone/levofloxacin/lopinavir/ritonavirThrombocytopenia following off-label use: case report
Reactions Weekly, 2021, 1836 (1) : 221 - 221
[7] Favipiravir/meropenem/vancomycinCholestatic liver injury following off-label use: case report
Reactions Weekly, 2021, 1840 (1) : 192 - 192
[8] Ascorbic-acid/favipiravir/methylprednisoloneLack of efficacy and off-label use: case report
Reactions Weekly, 2022, 1932 (1) : 105 - 105
[9] Camrelizumab/rivoceranibHypertension, leucopenia and thrombocytopenia following off-label use: case report
Reactions Weekly, 2022, 1895 (1) : 111 - 111
[10] CobimetinibExtremity swelling, thrombocytopenia and diarrhoea following off-label use: case report
Reactions Weekly, 2022, 1912 (1) : 158 - 158

← 1 2 3 4 5 →